A Phase 1 interventional study of linagliptin/metformin(high dose) and Linagliptin/metformin(low dose) in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-08-06.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of the trial is to assess the relative bioavailability of fixed dose combination tablets of linagliptin and metformin compared to the administration of two single tablets (linagliptin and metformin ) in Chinese subjects. The availability of a fixed dose combination tablet is expected to significantly enhance patients' compliance with antidiabetic treatment., in particular with concern to the frequent polypharmacy in diabetic patients.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (high dose) tablets single dose in randomized order
Drug: linagliptin/metformin(high dose)
24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (low dose) tablets single dose in randomized order
Drug: Linagliptin/metformin(low dose)
Drug pages: Linagliptin · Metformin
patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (High dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.
Drug pages: Linagliptin · Metformin
patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (Low dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.
Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72)
Time frame: 1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.
Maximum Measured Concentration (Cmax) of Linagliptin.
Time frame: 1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.
Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval 0 to the Last Quantifiable Concentration (AUC0-tz)
Time frame: 1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.
Maximum Measured Concentration (Cmax) of Metformin
Time frame: 1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.
Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity) for Linagliptin
AUC0-infinity is based on predicted last concentration values.
Time frame: 1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.
AUC(0-infinity) for Metformin
AUC0-infinity is based on predicted last concentration values.
Time frame: 1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.
AUC0-tz for Linagliptin
Time frame: 1 hour (h) prior to drug administration, 20 minutes (min), 40 min, 1 h, 1 h 30 min, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 24 h, 34 h, 48 h and 72 h thereafter.
| Milestone | Lina 2.5mg, Metformin 850mg | Lina 2.5mg, Metformin 500mg |
|---|---|---|
| Started | 24 | 24 |
| Completed | 23 | 24 |
| Not completed | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| nmol*h/L | Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet | Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets | Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet | Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets |
|---|---|---|---|---|
| Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72) | 248 ± 14.5 | 251 ± 15.3 | 266 ± 22.1 | 264 ± 23.8 |
| nmol/L | Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet | Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets | Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet | Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets |
|---|---|---|---|---|
| Maximum Measured Concentration (Cmax) of Linagliptin. | 6.90 ± 23.1 | 6.81 ± 18.2 | 7.54 ± 35.4 | 6.77 ± 25.9 |
| ng*h/mL | Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet | Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets | Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet | Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets |
|---|---|---|---|---|
| Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval 0 to the Last Quantifiable Concentration (AUC0-tz) | 11700 ± 27.9 | 12100 ± 23.2 | 8240 ± 20.8 | 8010 ± 21.3 |
| ng/mL | Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet | Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets | Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet | Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets |
|---|---|---|---|---|
| Maximum Measured Concentration (Cmax) of Metformin | 1680 ± 34.8 | 1780 ± 26.0 | 1220 ± 29.1 | 1190 ± 27.2 |
AUC0-infinity is based on predicted last concentration values.
| nmol*h/L | Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet | Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets | Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet | Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets |
|---|---|---|---|---|
| Area Under the Concentration Time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity) for Linagliptin | 471 ± 29.8 | 433 ± 22.2 | 483 ± 32.5 | 541 ± 36.4 |
AUC0-infinity is based on predicted last concentration values.
| ng*h/mL | Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet | Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets | Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet | Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets |
|---|---|---|---|---|
| AUC(0-infinity) for Metformin | 12200 ± 25.8 | 12500 ± 23.0 | 8440 ± 19.3 | 8210 ± 20.3 |
| nmol*h/L | Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet | Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets | Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet | Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets |
|---|---|---|---|---|
| AUC0-tz for Linagliptin | 248 ± 14.5 | 251 ± 15.3 | 266 ± 22.1 | 264 ± 23.8 |
Collected over First treatment with study drug until End-of-Study (which was 7 to 14 days after study drug treatment in Visit 3), i.e. 7 weeks plus 4 to 11 days after first treatment with study drug. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet | — | 0/23 (0%) | 0/23 (0%) |
| Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets | — | 0/24 (0%) | 2/24 (8.3%) |
| Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet | — | 0/24 (0%) | 0/24 (0%) |
| Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets | — | 0/24 (0%) | 2/24 (8.3%) |
| Event | Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet | Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets | Linagliptin 2.5 mg, Metformin 500 mg as FDC Tablet | Linagliptin 2.5 mg, Metformin 500 mg as Single Tablets |
|---|---|---|---|---|
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/23 | 2/24 | 0/24 | 2/24 |
| Age Continuous(years) | Lina 2.5mg, Metformin 850mg | Lina 2.5mg, Metformin 500mg | Total |
|---|---|---|---|
| Mean | 27.8 ± 4.4 | 28.6 ± 4.8 | 28.2 ± 4.6 |
| Sex: Female, Male(Participants) | Lina 2.5mg, Metformin 850mg | Lina 2.5mg, Metformin 500mg | Total |
|---|---|---|---|
| Female | 12 | 12 | 24 |
| Male | 12 | 12 | 24 |
The record gives a start of Feb 2012, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Linagliptin · Metformin